SERA
NASDAQ
US
Sera Prognostics, Inc. - Class A Common Stock
$2.01
▼ $-0.06
(-2.90%)
Vol 15K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$113.9M
ROE
-41.7%
Margin
-34343.2%
D/E
0.00
Beta
0.91
52W
$1–$9
Wall Street Consensus
9 analysts · Apr 20264
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
ATYR
aTyr Pharma Inc
$76.7M
FBIO
Fortress Biotech Inc
P/E 28.5
$113.6M
GANX
Gain Therapeutics Inc
$123.8M
INO
Inovio Pharmaceuticals Inc
$119.5M
COEP
Coeptis Therapeutics Holdings Inc
$76.1M
XGN
Exagen Inc
$137.8M
EXOZ
eXoZymes Inc
$91.4M
PMVP
PMV Pharmaceuticals Inc
$66.5M
BYSI
Beyondspring Inc
$67.0M
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.19 | $-0.16 | +$0.03 |
| Sep 2025 | $-0.20 | $-0.16 | +$0.04 |
| Jun 2025 | $-0.23 | $-0.16 | +$0.07 |
| Mar 2025 | $-0.23 | $-0.20 | +$0.03 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -45.9% | -45.9% | -45.9% | -45.9% | -45.9% | -41.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -47329.4% | -30306.5% | -30306.5% | -30306.5% | -30306.5% | -34343.2% |
| Gross Margin | -141.2% | -16.7% | -16.7% | -16.7% | -16.7% | -62.1% |
| D/E Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.00 |
| Current Ratio | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 | 1.89 |
Key Ratios
ROA (TTM)
-31.8%
P/S (TTM)
1198.47
P/B
5.8
EPS (TTM)
$-0.77
CF/Share
$-1.20
Rev Growth 3Y
-1.3%
52W High
$8.73
52W Low
$1.37
$1.37
52-Week Range
$8.73
How does SERA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SERA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1198.5
▲
9227%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
5.8
▲
134%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SERA profitability vs Biotechnology peers
ROE
-41.7%
▲
38%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-34343.2%
▼
11877%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
-62.1%
▼
179%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-31.8%
▲
32%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
SERA financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
1.9
▼
57%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.9
▼
6%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
SERA fundamentals radar
SERA
Peer median
Industry
SERA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
SERA vs peers: key metrics
Latest News
No related news yet